AnxA2 overexpression has been associated with resistance to gemcitabine in PDA, and patients with high levels of AnxA2 expression in their tumors have shorter disease-free survival rates and worse overall survival than those with low expression levels [22]. The gene discussed is ANXA2; the disease is Patent ductus arteriosus.